SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,111,631. The last known price of Bitcoin is 68,229.80907922 USD and is down -4.02 over the last 24 hours. It is currently trading on 12780 active market(s) with $42,739,134,877.94 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins sharp selloff and reports of heavy leveraged-position liquidations are driving the conversation, with traders debating whether the move marks capitulation or signals more downside. Some see a buying opportunity and expect a bounce, while others cite weak support and fear of further crypto-market losses.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.0099454 USD and is down -2.36 over the last 24 hours. It is currently trading on 1896 active market(s) with $2,532,309,467.05 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRP is drawing attention after a sharp slide alongside Bitcoin and the broader crypto market, with traders pointing to market-wide selling rather than a confirmed XRP-specific catalyst. The break below a key psychological level has fueled fears of further losses, while other traders see an oversold dip and are accumulating.

Dogecoin (DOGE) is a cryptocurrency . Users are able to generate DOGE through the process of mining. Dogecoin has a current supply of 156,738,272,860.16806072. The last known price of Dogecoin is 0.06457313 USD and is down -2.71 over the last 24 hours. It is currently trading on 1545 active market(s) with $672,498,596.98 traded over the last 24 hours. More information can be found at http://dogecoin.com/.

Dogecoin

Dogecoins sharp drop alongside a broader crypto selloff dominates the discussion, with traders worried about fresh multi-year lows and further losses. Others see the weakness as a buying opportunity, citing dip-buying and possible technical signs of a rebound.

Ethereum (ETH) is a cryptocurrency . Ethereum has a current supply of 122,215,668.80579185. The last known price of Ethereum is 1,929.81008702 USD and is down -4.05 over the last 24 hours. It is currently trading on 14342 active market(s) with $15,325,408,368.61 traded over the last 24 hours. More information can be found at https://www.ethereum.org/.

Ethereum

Ethereum is caught in a broad crypto selloff, with traders citing Bitcoin weakness and forced liquidations alongside wider risk-off pressure and macro concerns. Sentiment is split between calls that the decline may be capitulation and expectations of further losses, while some traders are buying the dip.

Zcash (ZEC) is a cryptocurrency . Users are able to generate ZEC through the process of mining. Zcash has a current supply of 16,964,197.93006099. The last known price of Zcash is 932.62986485 USD and is down -2.50 over the last 24 hours. It is currently trading on 670 active market(s) with $1,142,095,783.67 traded over the last 24 hours. More information can be found at https://z.cash/.

Zcash

Zcash is drawing attention amid a steep pullback from recent highs, with traders discussing weakening support, possible liquidations and broader crypto-market pressure. The community is split between calling the drop an oversold buying opportunity and expecting more downside; some also point to Zcashs privacy features and network upgrades as reasons for longer-term optimism.

Hedera (HBAR) is a cryptocurrency launched in 2017. Hedera has a current supply of 50,000,000,000 with 44,327,140,678.86417527 in circulation. The last known price of Hedera is 0.06118377 USD and is down -3.83 over the last 24 hours. It is currently trading on 468 active market(s) with $73,346,897.90 traded over the last 24 hours. More information can be found at https://www.hedera.com/.

Hedera Hashgraph

HBAR is drawing attention after traders linked its sharp rally to Nvidias involvement in the Hedera Council and Hederas presence in Nvidias Open Agent Safety Platform. The community is split between viewing the AI association as a meaningful catalyst and calling the move hype or a sell-the-news pump as the token pulls back.

Quant (QNT) is a cryptocurrency and operates on the Ethereum platform. Quant has a current supply of 14,881,364 with 12,072,738 in circulation. The last known price of Quant is 159.21664083 USD and is down -1.76 over the last 24 hours. It is currently trading on 414 active market(s) with $110,625,382.40 traded over the last 24 hours. More information can be found at https://quant.network/.

Quant

Quant is drawing attention after a steep selloff alongside broader crypto weakness, with traders debating whether the pullback has further to run or is a buying opportunity. Many are accumulating on weakness based on the long-term tokenized-banking and Clearing House thesis, while skeptics question the tokens near-term demand before the network goes live.

Solana (SOL) is a cryptocurrency launched in 2020. Solana has a current supply of 637,493,507.45679271 with 591,519,914.8768357 in circulation. The last known price of Solana is 77.75210106 USD and is down -4.52 over the last 24 hours. It is currently trading on 1189 active market(s) with $3,771,510,230.13 traded over the last 24 hours. More information can be found at https://solana.com.

Solana

Solana is drawing attention amid a sharp broader crypto selloff, with traders noting heavy downside pressure and a break below a closely watched support area as Bitcoin and other major tokens also fall. The community is split between buying the dip and expecting further declines, with some attributing the weakness to political or security concerns but no single explanation emerging as consensus.

Cardano (ADA) is a cryptocurrency launched in 2017. Cardano has a current supply of 44,994,648,344.194204 with 36,816,370,531.313927 in circulation. The last known price of Cardano is 0.16792499 USD and is down -4.07 over the last 24 hours. It is currently trading on 1752 active market(s) with $304,416,326.91 traded over the last 24 hours. More information can be found at https://www.cardano.org.

Cardano

ADAs steep decline amid broader crypto weakness is driving bearish talk of further losses and frustration with its prolonged underperformance. Traders are split between selling or waiting for lower levels and buying the dip for a rebound; some also cite Charles Hoskinsons comments that Cardanos roadmap is complete as a source of disappointment, while bullish squeeze calls remain speculative.

Zillow Group, Inc. engages in the provision of real estate and home-related information marketplaces on mobile and the web. The company was founded by Richard N. Barton and Lloyd D. Frink in December 2004 and is headquartered in Seattle, WA.

Zillow Group Inc - Ordinary Shares - Class C

Zillow Group Inc Class C

Zillows earnings update and weaker outlook have fueled a sharp selloff, with traders pointing to rising mortgage rates and a sluggish housing market as headwinds. The community is split between bearish concerns about further downside and bulls viewing the decline as a buying opportunity.

statis crypto Watchlist

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What Makes Protara Therapeutics (TARA) a New Buy Stock

Protara Therapeutics (TARA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Protara Therapeutics Reports 55% Complete Response Rate In Bladder Cancer Study

Protara reports updated Phase 2 data showing durable responses and favorable safety for TARA-002 in bladder cancer patients.read more...

Equities Analysts Offer Predictions for TARA FY2028 Earnings

Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) - Equities research analysts at HC Wainwright raised their FY2028 EPS estimates for shares of Protara Therapeutics in a research note issued to investors on Wednesday, April 29th. HC Wainwright analyst A. Maldonado now expects that the company w...

Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of Protara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the six research firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, f...

Stock Traders Buy Large Volume of Protara Therapeutics Call Options (NASDAQ:TARA)

Protara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) was the recipient of some unusual options trading on Wednesday. Stock traders bought 2,120 call options on the stock. This represents an...

Jacqueline Zummo Sells 22,598 Shares of Protara Therapeutics (NASDAQ:TARA) Stock

Protara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) insider Jacqueline Zummo sold 22,598 shares of Protara Therapeutics stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $5.26, for a total value of $118,865.48. Following the completion of the sale...

Insider Selling: Protara Therapeutics (NASDAQ:TARA) Insider Sells 22,598 Shares of Stock

Protara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) insider Jacqueline Zummo sold 22,598 shares of the business's stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $5.26, for a total transaction of $118,865.48. Following the transaction, the...

Protara Therapeutics, Inc. (NASDAQ:TARA) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Protara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) has earned a consensus rating of "Moderate Buy" from the seven ratings firms that are presently covering the company, Marketbeat reports...

Protara Therapeutics, Inc. (NASDAQ:TARA) Sees Large Increase in Short Interest

Protara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) was the target of a significant increase in short interest in the month of March. As of March 13th, there was short interest totaling...

Protara Therapeutics, Inc. (NASDAQ:TARA) Short Interest Up 48.0% in February

Protara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) saw a large increase in short interest in the month of February. As of February 27th, there was short interest totaling 4,895,488 shares, an...

Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman and Jacqueline Zummo in March 2006 and is headquartered in New York, NY.

Protara Therapeutics Inc

Bullish Sentiment

<ul class="summary-bullets"><li>The company reported strong efficacy and a clean safety profile from its ongoing Phase 2 Advanced-2 bladder cancer trial.</li><li>Durability signals were notable, with 68% of BCG-unresponsive patients and 66% of BCG-naive patients cancer-free at six months.</li><li>Safety and tolerability remained favorable, with mostly mild, short-lived side effects and no severe treatment-related adverse events.</li></ul>Shares of Protara Therapeutics, Inc. (TARA) fell nearly 15% in extended trading on Monday, even as the company reported strong response rates and favorable tolerability in its ongoing Phase 2 bladder cancer trial.TARA stock jumped 9% on Monday’s regular session to $7.43, hitting its highest levels in three months and its best session in nearly a month.<h2 class="st-heading-2">Phase 2 Trial Shows Strong Efficacy Signals</h2>The after-hours move followed updated interim results from Protara’s open-label Phase 2 Advanced-2 trial, which is testing TARA-002 as a bladder-delivered treatment in patients with high-risk non-muscle invasive bladder cancer. The study includes patients whose cancer has returned despite standard BCG therapy, as well as patients who have not previously received BCG, a commonly used bladder cancer treatment.Among patients whose cancer recurred after standard BCG treatment, 66% of the 35 patients evaluated achieved a complete response at some point during the study. Among those assessed at six months, 68% were cancer-free, while 33% remained cancer-free at 12 months. Statistical estimates showed a 71% probability of maintaining a complete response for at least six months, and 62% of patients who required re-treatment later achieved a complete response within six months.In patients who had not previously received BCG, 72% achieved a complete response at some point, with 66% cancer-free at six months and 58% at 12 months. Statistical estimates indicated a 73% probability of maintaining a response for at least six months, and 67% of re-treated patients achieved a complete response by six months.<h2 class="st-heading-2">Safety Profile Remains Clean</h2>The company also said the trial noted a favorable safety and tolerability profile for TARA-002. Most treatment-related adverse events were Grade 1 and transient, with no Grade 3 or higher events reported and no treatment-related serious adverse events observed. No patients discontinued treatment due to adverse events.“In addition to demonstrating impressive efficacy and safety, TARA-002 overcomes the limitations of existing NMIBC treatments that burden patients as well as urologists and their practices,” said CEO Jesse Shefferman.The most commonly reported side effects included dysuria, bladder spasm, fatigue and urinary urgency, with bladder irritation typically resolving within hours to a few days after administration.<h2 class="st-heading-2">Analysts Remain Bullish Despite Selloff</h2>Despite the after-hours decline, analyst sentiment toward the stock remains positive. Koyfin estimates show a 12-month average price target of $25.5, implying a potential upside of more than 240% from current levels.The stock carries a consensus rating of ‘Strong Buy’, with seven covering analysts. Of them, one rates the stock a ‘Strong Buy’, while six rate it ‘Buy.’<h2 class="st-heading-2">Advanced-3 Trial Planned for 2026</h2>Protara said it expects to complete enrollment in the Advanced-2 trial cohort of patients whose cancer returned after standard BCG treatment in the second half of 2026. Enrollment in the cohort of patients who had not previously received BCG is already complete, with 31 patients enrolled.The company also said it remains on track to initiate the Advanced-3 registrational trial in patients who have not previously received BCG in the second half of 2026, positioning TARA-002 for potential late-stage development across multiple high-risk non-muscle invasive bladder cancer populations.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for TARA was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/tara_ss_png_6da5855253.webp" alt="tara ss.png" width="967" height="141"><figcaption>TARA sentiment and message volume as of February 24 | Source: Stocktwits</figcaption></figure>One user said, “I am not sure why this stock did a nose dive after hours unless the results were widely misinterpreted.”<stembedurl>https://stocktwits.com/GammaRadiated/message/645688600</stembedurl>Another user said, “Don't catch this falling knife!! buy into tara low,” and added that investors can expect a profit on Tuesday.<stembedurl>https://stocktwits.com/RoadToAHouse/message/645675757</stembedurl>TARA stock has risen 40% year to date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

TARA stock has risen 40% year to date. (Photo credit: Getty Images)

Does TARA Stock’s 15% After-Hours Slump Signal A Bargain After New Bladder Cancer Data?

The company is on track to initiate the Advanced-3 registrational trial in patients who have not previously received BCG in the second half of 2026.

Equity

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$2.53
Prev Close	$2.44
Open	$2.49
Dividend Yield	0.00%
50-Day Moving Average	$2.89
Beta	1.23
Avg. Volume	1.28M
PE Ratio	-1.83

52-Week High	$7.82
52-Week Low	$2.09
Market Capitalization	$155.77M
EPS (Annual)	-$1.34
Price to Book	1.08
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

TARA Fundamentals